ActTrader voted as the ‘The Best Multi-Asset Platform’ at The Forex Expo, Dubai 2021
2.11.2021 12:56:00 EET | Business Wire | Press release
ActTrader, now a Finvasia Group Company, won this year’s best Multi-Asset Platform award at largest trading event in the MENA region - The Forex Expo, Dubai 2021. The award recognises businesses that push the boundaries of innovation in the Fintech space.
ActTrader provides customised solutions and dedicated technical infrastructure to some of the biggest forex brokers, hedge funds, ECN venues, multi-asset exchanges and financial institutions. They offer adaptive trading technology that works seamlessly through a single feature-rich application, eliminating the need of integrating with third-party applications.
When contacted, Sarvjeet Singh, co-founder Finvasia said he feels humbled to have achieved this milestone within the first year of their acquisition of ActTrader. "We envisage to build innovative technology solutions that meet the evolving needs of current and future needs of financial institutions," he further added.
The Fore Expo is one of the biggest trading event that hosts prestigious brokers, technology providers, financial institutions, banks, retail traders and media houses from the financial services industry. With more than 7000 in attendance, it is a place for people from the finance industry to coming together in one place.
"ActTrader has been making a buzz ever since its inception in 2000. It has helped thousands of multi-asset brokers and financial institutions globally to revolutionise their trading operations, hedge their risk, and yield profits with its tailor-made solutions." - Ilya Sorokin, Founder & CEO, ActTrader.
About ActTrader
ActTrader is a leading provider of multi-asset trading technologies with award-winning products including the state-of-the-art trading platform, order execution engine, CRM solutions, Auto Trading Algorithms, White Label Solutions, STP Liquidity through FIX API, Multi-platform bridge, AI-based social trading, crypto exchange, and other value-added services.
To expand the company’s B2B offerings, ActTrader joined forces with Finvasia Group- a multinational organisation that owns various brands in the financial services, healthcare, real estate, blockchain, and technology sectors.
Know more: https://acttrader.com/
About FINVASIA Group
FINVASIA is a multi-disciplinary, multinational organisation registered with regulatory bodies across the world, via its subsidiaries and sister concerns, in various capacities including SEC, USA (152771), CYSEC (367/18), FCA (850138), BaFin (157125), ACPR (85051), CONSOB (5151), CNVM (4892), Finanstilsynet (FT00118545) and more.
In India, Finvasia is registered with the Reserve Bank of India as an NBFC, NSE as a Professional Clearing member (M51912), BSE (4043), MCX (55135), and NCDEX as Trading Member (01259), AMFI (103331) and CDSL as Depository Participant (12084300).
Know more: https://finvasia.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005647/en/
Contact information
Media Contact
Ms. Sandeep Samra
media@stackflow.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom